SCHEMBL21185374

SCHEMBL21185374

COc1cccc(C(=O)Nc2cccc(-c3cn(Cc4ccccc4)nn3)c2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.69
DAPK3 O43293 3/20 0.69
PAK4 O96013 3/20 0.69
CDK2 P24941 3/20 0.69
CLK2 P49760 3/20 0.69
CDK7 P50613 3/20 0.69
PRKX P51817 3/20 0.69
CDK5 Q00535 3/20 0.69
CAMK2D Q13557 3/20 0.69
DYRK1A Q13627 3/20 0.69
MELK Q14680 3/20 0.69
HIPK2 Q9H2X6 3/20 0.69
STK17A Q9UEE5 3/20 0.69
FLT3 P36888 2/20 0.69
GSK3A P49840 2/20 0.69
JAK2 O60674 2/20 0.69
ROCK2 O75116 2/20 0.69
MAP4K4 O95819 2/20 0.69
PRKACA P17612 2/20 0.69
CSNK1A1 P48729 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22566549 0.88 TSHR (0.63) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL22566548 0.88 TSHR (0.62) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL22566519 0.87 HDAC3 (0.70) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL22566619 0.87 HDAC3 (0.58) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL21185375 0.84 TSHR (0.65) ALOX15TSHRHSD17B10MEN1KMT2A
SCHEMBL22566562 0.80 HDAC3 (0.60) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL28721392 0.80 TSHR (0.49) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL28721391 0.80 TSHR (0.49) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL22566338 0.79 GPR55 (0.55) CDC7DAPK3PAK4CDK2CLK2
SCHEMBL19708171 0.78 MEN1 (0.78) CDC7DAPK3PAK4CDK2CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250086-A1 METHIONINE METABOLIC PATHWAY INHIBITORS MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) 2023-08-10 US disclosed
US-20230250086-A1 METHIONINE METABOLIC PATHWAY INHIBITORS MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) 2023-08-10 US disclosed
US-11639345-B2 Methionine metabolic pathway inhibitors MIGAL—GALILEE RESEARCH INSTITUTE LTD. (IL) 2023-05-02 US disclosed
US-11639345-B2 Methionine metabolic pathway inhibitors MIGAL—GALILEE RESEARCH INSTITUTE LTD. (IL) 2023-05-02 US disclosed
US-20200331872-A1 METHIONINE METABOLIC PATHWAY INHIBITORS MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) 2020-10-22 US disclosed
WO-2019142192-A1 NEW METHIONINE METABOLIC PATHWAY INHIBITORS GAVISH-GALILEE BIO APPLICATIONS LTD. (IL) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639345-B2 Methionine metabolic pathway inhibitors GSS, MTR, CTH CDC7 1348/4885DAPK3 3140/4885PAK4 1785/4885
US-20200331872-A1 METHIONINE METABOLIC PATHWAY INHIBITORS GSS, MTR, CTH CDC7 1348/4885DAPK3 3140/4885PAK4 1785/4885
US-20230250086-A1 METHIONINE METABOLIC PATHWAY INHIBITORS GSS, MTR, CTH CDC7 1348/4885DAPK3 3140/4885PAK4 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.